KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Inventory (2017 - 2025)

Historic Inventory for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $7.9 million.

  • Aquestive Therapeutics' Inventory rose 1229.17% to $7.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.9 million, marking a year-over-year increase of 1229.17%. This contributed to the annual value of $6.0 million for FY2024, which is 1071.06% down from last year.
  • Latest data reveals that Aquestive Therapeutics reported Inventory of $7.9 million as of Q3 2025, which was up 1229.17% from $8.1 million recorded in Q2 2025.
  • Over the past 5 years, Aquestive Therapeutics' Inventory peaked at $8.1 million during Q2 2025, and registered a low of $2.8 million during Q1 2021.
  • For the 5-year period, Aquestive Therapeutics' Inventory averaged around $5.9 million, with its median value being $6.7 million (2022).
  • Per our database at Business Quant, Aquestive Therapeutics' Inventory tumbled by 1169.03% in 2021 and then skyrocketed by 13489.35% in 2022.
  • Over the past 5 years, Aquestive Therapeutics' Inventory (Quarter) stood at $4.0 million in 2021, then soared by 43.14% to $5.8 million in 2022, then grew by 17.11% to $6.8 million in 2023, then dropped by 10.71% to $6.0 million in 2024, then skyrocketed by 30.44% to $7.9 million in 2025.
  • Its last three reported values are $7.9 million in Q3 2025, $8.1 million for Q2 2025, and $7.2 million during Q1 2025.